logo

For the Inventor, By the Inventor

Osaka, Japan

Ono Pharmaceutical Co., Ltd.

USPTO Granted Patents = 575

% Expired Patents = 35.5



Trademarks = 7

Forward Citations = 6,439

Loading Chart...
Loading Chart...

583 inventors (with patents filed for the assignee):

goldMedal Shiro Shibayama (49 out of 52 patents)

silverMedal Masaki Hayashi (43 out of 46 patents)

bronzeMedal Yoshinobu Arai (40 out of 41 patents)

4.  Shuichi Ohuchida (40 out of 43 patents)

5.  Hiroyuki Ohno (32 out of 35 patents)

6.  Kousuke Tani (30 out of 33 patents)

7.  Nobuyuki Hamanaka (30 out of 30 patents)

8.  Tasuku Honjo (27 out of 40 patents)

9.  Masaaki Toda (27 out of 29 patents)

10.  Kaoru Kobayashi (24 out of 40 patents)

11.  Hisao Nakai (24 out of 25 patents)

12.  Kazuyuki Ohmoto (23 out of 27 patents)

13.  Katsuhiro Imaki (23 out of 23 patents)

14.  Jun Takeuchi (21 out of 23 patents)

15.  Yoshikazu Takaoka (21 out of 23 patents)


Core Competencies:
Bispecific Antibody
STING Agonistic Compound
Immune Checkpoint Inhibitor
Cancer Treatment
S1P5 Receptor Agonist
HMGN Partial Peptide
KDM5 Inhibitor
Combination Therapy
Chimeric Antigen Receptor
Purinone Derivative
Activators of TREK Channels
BRK Inhibitory Compound

575 patents:

1. 12698286 - Compound having KDM5 inhibitory activity and pharmaceutical use thereof (2026-08-04),
2. 12630544 - Compound, α-synuclein aggregate binder, and use thereof (2026-05-19),
3. 12630510 - EP2 antagonist (2026-05-19),
4. 12600730 - Substituted cyclopenta[c]pyrroles as ABHD6 antagonists (2026-04-14),
5. 12571799 - Biomarkers for determining the efficacy of immune checkpoint inhibitors (2026-03-10),
6. 12497377 - Tricyclic spiro compound (2025-12-16),
7. 12459890 - Salt and crystal form of compound having agonistic activity to S1P5 receptor (2025-11-04),
8. 12447150 - Treatment of cancer by combination of immune checkpoint inhibitor and folfirinox therapy (2025-10-21),
9. 12325746 - Bispecific antibody (2025-06-10),
10. 12269817 - Compound having KDM5 inhibitory activity and pharmaceutical use thereof (2025-04-08),
11. 12258308 - Benzene derivative (2025-03-25),
12. 12240903 - Biomarkers for determining the effectiveness of immune checkpoint inhibitors (2025-03-04),
13. 12234289 - Immunosuppresive agent (2025-02-25),
14. 12201603 - Bicyclic compound and use thereof for medical purposes (2025-01-21),
15. 12186392 - Combination therapy of an anti CD20 antibody with a BTK inhibitor (2025-01-07),
Company Overview
Ono Pharmaceutical Co., Ltd., headquartered in Osaka, Japan, is a leading biopharmaceutical company specializing in the development of innovative cancer therapies. The company focuses on advanced technologies such as bispecific antibodies, immune checkpoint inhibitors, and STING agonistic compounds, aiming to enhance treatment efficacy and patient outcomes. Ono is committed to addressing unmet medical needs through its research in combination therapies and various receptor agonists, positioning itself at the forefront of oncology advancements.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

575 Patents

#44 in Osaka

#352 in Japan

#1,710 in the World

Osaka, JP
Osaka, Japan

Ono Pharmaceutical Co., Ltd.

Forward Citations = 6,439

583 inventors:

goldMedal Shiro Shibayama (49 out of 52 patents)

silverMedal Masaki Hayashi (43 out of 46 patents)

bronzeMedal Yoshinobu Arai (40 out of 41 patents)

4.  Shuichi Ohuchida (40 out of 43 patents)

5.  Hiroyuki Ohno (32 out of 35 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Ono Pharmaceutical Co., Ltd.. Retrieved from https://idiyas.com/company/ono-pharmaceutical-company

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…